Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells

被引：4
|
作者：
Xu, Dehui [1 ]
Cui, Qingjie [2 ]
Xu, Yujing [1 ]
Chen, Zeyu [1 ]
Xia, Wenjie [1 ]
Yang, Yanjie [3 ]
Liu, Dingxin [1 ]
机构：
[1] Xi An Jiao Tong Univ, Ctr Plasma Biomed, State Key Lab Elect Insulat & Power Equipment, Xian 710049, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Sch, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Sch, Dept Cardiovasc Med, 277 Yanta West Rd, Xian 710049, Shaanxi, Peoples R China
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
基金：
中国博士后科学基金; 中国国家自然科学基金;
关键词：
Cold atmospheric plasma; cyp1a1; drug resistance; multiple myeloma (MM); notch; MULTIPLE-MYELOMA; RESISTANCE; ACTIVATION; DEATH;
D O I：
10.21037/tcr.2019.10.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. Methods: Here, we combined chemotherapy with a newly developed technology, cold atmospheric plasma, to enhance drug sensitivity. Results: We found that plasma treatment had a synergistic anti-cancer effect with a first line drug (bortezomib). Based on our previous study, we further found that plasma treatment could inhibit Notch pathway and down-regulate cyp1a1 expression and enzyme activity, which contributing to the enhanced drug sensitivity to bortezomib after combination of bortezomib with gas plasma. Conclusions: Our results showed a new strategy to overcome drug resistance by combination of traditional chemotherapy with cold atmospheric plasma.
引用
收藏
页码：2841 / +
页数：10
相关论文
共 50 条
  • [1] Cyp1a1 is involved in drug resistance to bortezomib in CD138- myeloma cells
    Yang, Yanjie
    Xu, Dehui
    Zhang, Ting
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21296 - 21303
  • [2] Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma
    Xu, Dehui
    Hu, Jinsong
    De Bruyne, Elke
    Menu, Eline
    Schots, Rik
    Vanderkerken, Karin
    Van Valckenborgh, Els
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 428 (04) : 518 - 524
  • [3] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury
    Shimizu, Yuki
    Sasaki, Takamitsu
    Yonekawa, Eri
    Yamazaki, Hirokazu
    Ogura, Rui
    Watanabe, Michiko
    Hosaka, Takuomi
    Shizu, Ryota
    Takeshita, Jun-ichi
    Yoshinari, Kouichi
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2021, 46 (04): : 167 - 176
  • [4] Metformin and chidamide synergistically suppress multiple myeloma progression and enhance lenalidomide/bortezomib sensitivity
    Mao, Jianping
    Chen, Ran
    Xue, Lianguo
    Zhu, Yuanxin
    Zhao, Lidong
    Wang, Juan
    ENVIRONMENTAL TOXICOLOGY, 2024, 39 (04) : 2452 - 2465
  • [5] Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib
    Nerini-Molteni, Silvia
    Ferrarini, Marina
    Cozza, Sara
    Caligaris-Cappio, Federico
    Sitia, Roberto
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 494 - 503
  • [6] Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
    Kraus, M.
    Bader, J.
    Overkleeft, H.
    Driessen, C.
    BLOOD CANCER JOURNAL, 2013, 3 : e103 - e103
  • [7] Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity
    Decaux, Olivier
    Clement, Monique
    Magrangeas, Florence
    Gouraud, Wilfried
    Charbonnel, Catherine
    Campion, Loic
    Loiseau, Herve Avet
    Minvielle, Stephane
    CANCER SCIENCE, 2010, 101 (04) : 889 - 897
  • [8] Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
    Muz, Barbara
    Azab, Feda
    de la Puente, Pilar
    Rollins, Scott
    Alvarez, Richard
    Kawar, Ziad
    Azab, Abdel Kareem
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [9] Inhibition of apoptosis may lead to the development of bortezomib resistance in multiple myeloma cancer cells
    Oksuzoglu, Emine
    Kozalak, Gul
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2021, 46 (01): : 63 - 69
  • [10] Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4′ hydroxy tangeretin
    Surichan, Somchaiya
    Arroo, Randolph R.
    Tsatsakis, Aristidis M.
    Androutsopoulos, Vasilis P.
    TOXICOLOGY IN VITRO, 2018, 50 : 274 - 284
12345